An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)

Shu-Fen Chiang; Kevin Chih-Yang Huang; William Tzu-Liang Chen; Tsung-Wei Chen; Tao-Wei Ke; K S Clifford Chao

doi:10.1080/2162402X.2021.1926074

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)

Oncoimmunology. 2021 May 14;10(1):1926074. doi: 10.1080/2162402X.2021.1926074.

Authors

Shu-Fen Chiang¹, Kevin Chih-Yang Huang^{2

3}, William Tzu-Liang Chen^{4

5

6}, Tsung-Wei Chen^{7

8}, Tao-Wei Ke^{6

9}, K S Clifford Chao^{5

7

10}

Affiliations

¹ Laboratory of Precision Medicine, Ministry of Health & Welfare Feng Yuan Hospital, Taichung, Taiwan.
² Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
³ Translation Research Core, China Medical University Hospital, China Medical University, Taichung, Taiwan.
⁴ Department of Colorectal Surgery, Hsinchu China Medical University Hospital, Hsinchu, Taiwan.
⁵ School of Medicine, China Medical University, Taichung Taiwan.
⁶ Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan.
⁷ Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan.
⁸ Department of Pathology, Asia University Hospital, Asia University, Taichung, Taiwan.
⁹ School of Chinese Medicine, China Medical University, Taichung, Taiwan.
¹⁰ Cancer Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.

Abstract

Formyl peptide receptor 1 (FPR1) plays a key regulatory role in innate and adaptive immunity. Recently, we reported that the CC genotype of FPR1-E346A (rs867228, c. 1037 A > C) is an independent biomarker for patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy (CCRT). Pharmacologic inhibition of FPR1 decreased the migration and infiltration of T lymphocytes into tumor microenvironment after CCRT.

Keywords: CCRT; DAMP; FPR1; ICD; antitumor immunity.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Chemoradiotherapy
Humans
Prognosis
Receptors, Formyl Peptide* / genetics
Rectal Neoplasms* / diagnosis
Rectal Neoplasms* / genetics
Tumor Microenvironment

Substances

FPR1 protein, human
Receptors, Formyl Peptide

Grants and funding

This study was supported by grants from China Medical University Hospital [DMR-109-249];Ministry of Health and Welfare [MOHW 110-TDU-B-212-144024];Ministry of Health and Welfare [MOHW110-12];Ministry of Science and Technology [MOST107-2314-B-039-057-MY3];Ministry of Science and Technology [MOST 107-2314-B-039-027-MY3];Feng Yuan Hospital of the Ministry of the Health and welfare [110-03].